{"prompt": "['Product: MK-3475', '60', 'Protocol/Amendment No.: 604-09', 'A subject must be discontinued from trial treatment but continue to be monitored in the trial', 'for any of the following reasons:', \"The subject or subject's legally acceptable representative requests to discontinue trial\", 'treatment.', 'Confirmed radiographic disease progression, as outlined in Section 7.1.5 (exception if', 'the Sponsor approves treatment continuation)', 'Note: Subjects with new asymptomatic brain metastasis may be eligible to continue', 'study treatment at the discretion of the investigator after consultation with the', 'Sponsor. Section 7.1.2.7.6 provides details regarding eligibility requirements and', 'subsequent radiographic assessments.', 'Unacceptable AEs, as described in Section 7.2', 'Any progression or recurrence of any malignancy, or any occurrence of another', 'malignancy that requires active treatment', 'Intercurrent illness other than another malignancy as noted above that prevents', 'further administration of treatment', 'Recurrent Grade 2 pneumonitis', 'Recurrent Grade 3 diarrhea', 'A confirmed positive serum pregnancy test', 'Noncompliance with trial treatment or procedure requirements', \"Investigator's decision to withdraw the subject\", 'Completion of 35 cycles of trial treatments (approximately 2 years)', 'Note: The number of treatments is calculated starting with the first dose. Subjects who stop', 'trial treatment after receiving 35 doses of pembrolizumab or saline placebo may be eligible', 'for the Second Course Phase (retreatment) if they progress after stopping trial treatment,', 'provided they meet the requirements detailed in Section 7.1.5.5. Only subjects who were', 'assigned to the pembrolizumab arm may be retreated in the Second Course Phase for up to an', 'additional 17 cycles (approximately 1 year).', 'For subjects who are discontinued from trial treatment but continue to be monitored in the', 'trial, all visits and procedures, as outlined in the trial flowchart, should be completed.', 'Discontinuation from trial treatment is \"permanent.\" Once a subject is discontinued, he/she', 'shall not be allowed to restart treatment.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '61', 'Protocol/Amendment No.: 604-09', '5.8.2 Withdrawal from the Trial', \"A subject must be withdrawn from the trial if the subject or subject's legally acceptable\", 'representative withdraws consent from the trial.', 'If a subject withdraws from the trial, they will no longer receive trial treatment or be', 'followed at scheduled protocol visits.', 'Specific details regarding procedures to be performed at the time of withdrawal from the trial', 'including the procedures to be performed should a subject repeatedly fail to return for', 'scheduled visits and/or if the study site is unable to contact the subject, as well as specific', 'details regarding withdrawal from Future Biomedical Research are outlined in Section 7.1.4', '- Other Procedures.', '5.9 Subject Replacement Strategy', 'A subject who is discontinued from trial treatment or withdraws from the trial will not be', 'replaced.', '5.10 Beginning and End of the Trial', 'The overall trial begins when the first subject signs the informed consent form. The overall', 'trial ends when the last subject completes the last study-related phone-call or visit, withdraws', 'from the trial or is lost to follow-up (i.e. the subject is unable to be contacted by the', 'investigator).', '5.11 Clinical Criteria for Early Trial Termination', 'Early trial termination will be the result of the criteria specified below:', 'The trial will be stopped early if the risk/benefit ratio to the trial population as a whole is', 'unacceptable.', 'Statistical criteria for stopping the trial are provided in Section 8.0.', 'Further recruitment in the trial or at 1 or more particular trial sites may be stopped due to', 'insufficient compliance with the protocol, Good Clinical Practice (GCP), or other applicable', 'regulatory requirements; procedure-related problems; or excessive number of', 'discontinuations for administrative reasons.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '62', 'Protocol/Amendment No.: 604-09', '6.0 TRIAL FLOW CHART', '6.1', 'Initial Treatment Phase', 'Screening', 'End of', 'Phase', 'Treatment Phase (3-Week Cycles)', 'Follow-up', 'Treatment', 'PFS', 'Screening', 'Safety', 'Survival', 'Follow-', 'Treatment Cycle', '1', '1', '1', '2', '2', '2', '3', '3', '3', '4', '4', '4', '5-35', 'Discon\u00b9', 'Follow-', 'Follow-', '(Visit 1)', 'up\u00b2', 'up', 'Visits\u00b3', 'up4', 'Day (in Cycle)', '1', '2&3', '8', '1', '2&3', '8', '1', '2&3', '8', '1', '2&3', '8', '1', 'NA', 'NA', 'NA', 'NA', 'Every 6', 'or 9', '30 Days', 'Weeks', 'At Time of', 'From', 'Scheduling Window', 'Every 8', '( 7', '-28 to -1', '+3', '1', '3', '1', '3', '1', '3', '1', '3', 'Discon', 'Last', 'Weeks', '(Days):5', '3', 'Dose', 'days)', '7 days', '+ 7', 'per', 'imaging', 'schedule', 'Administrative Procedures', 'Informed Consent', 'X', 'Informed Consent for', 'Future Biomedical', 'X', 'Research (optional)', 'Inclusion/Exclusion', 'X', 'Criteria', 'Subject Identification', 'X', 'Card', 'Demographics and', 'X', 'Medical History', 'Prior and Concomitant', 'X', 'X', 'X', 'X', 'X', 'X', 'Medications6', 'SCLC Disease Details', 'X', 'Obtain allocation number', 'using IVRS', 'Clinical Procedures/Assessments', 'Review Adverse Events', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X7', 'X7', 'X7', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}